Pfizer Reports the Data from P-III (TALAPRO-2) Study of Talzenna Plus Xtandi for Treating mCRPC
Shots:
- Pfizer has reported topline results from the P-III (TALAPRO-2) trial assessing Talzenna (0.5mg/day) + Xtandi (160mg/day) vs PBO to treat mCRPC patients (N=1,035) being divided in two arms of all-comers (n=805, 169 with HRR mutations) & HRR mutation +ve (n=399, 169 from arm 1 & 230 in arm 2)
- Study depicted a significantly improved OS and an improved rPFS that maintained during the final analysis in both the arms. These results confirm the earlier findings published in The Lancet
- Safety profile aligned with the previously established results of each drug. Data will be highlighted at the future conferences and will be shared with regulatory authorities worldwide, seeking approval for the same
Ref: Pfizer | Image: Pfizer
Related News:- Valneva and Pfizer Present P-II (VLA15-221) Study Data of VLA15 Vaccine for Lyme Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
